Inhibition of cytochrome P4502C9 activity in vitro by 5-hydroxytryptamine and adrenaline

被引:15
|
作者
Gervasini, G
Martínez, C
Agúndez, JAG
García-Gamito, FJ
Benítez, J
机构
[1] Univ Extremadura, Fac Med, Dept Farmacol, E-06071 Badajoz, Spain
[2] INSALUD Hosp Merida, Serv Gen Surg, Badajoz, Spain
来源
PHARMACOGENETICS | 2001年 / 11卷 / 01期
关键词
diclofenac; CYP2C9; microsomes;
D O I
10.1097/00008571-200102000-00004
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
In the present study, the occurrence of a modulatory effect of 14 neurotransmitters, precursors and metabolites on the cytochrome P450 2C9 (CYP2C9) enzyme activity, as determined by diclofenac 4-hydroxylation, was studied in human liver microsomes. Two indoleamines, 5-hydroxytryptamine (5-HT) and adrenaline, showed a non-competitive-type inhibitory effect of approximately 90% of the diclofenac 4-hydroxylase activity, with K-i values of 63.5 (0.7 and 156 (89.3 muM, respectively. The rest of substances analysed were weak inhibitors or had no inhibitory effect, CYP2C subfamily is present in human brain, although CYP2C9 isozyme has not yet been identified in this tissue, and CYP2C9 is involved in the metabolism of psychoactive drugs. Therefore, the fact that endogenous compounds could modulate the CYP2C9 activity, suggests that an hypothetical local activity of brain CYP2C9 might be susceptible to regulatory mechanisms. The possible clinical implications of this modulation are discussed. Pharmacogenetics 11:29-37 (C) Lippincott Williams & Wilkins.
引用
收藏
页码:29 / 37
页数:9
相关论文
共 50 条
  • [1] Effects of avasimibe on cytochrome P4502C9 expression in vitro and in vivo
    Sahi, J
    Stern, RH
    Milad, MA
    Rose, KA
    Gibson, G
    Zheng, XX
    Stilgenbauer, L
    Sadagopan, N
    Jolley, S
    Gilbert, D
    LeCluyse, EL
    DRUG METABOLISM AND DISPOSITION, 2004, 32 (12) : 1370 - 1376
  • [2] Study of recombinant cytochrome P4502C9 activity with diclofenac by MEKC
    Konecny, Jiri
    Jurica, Jan
    Tomandl, Josef
    Glatz, Zdenek
    ELECTROPHORESIS, 2007, 28 (08) : 1229 - 1234
  • [3] Warfarin dosing and cytochrome P4502C9 polymorphisms
    Joffe, HV
    Xu, RL
    Johnson, FB
    Longtine, J
    Kucher, N
    Goldhaber, SZ
    THROMBOSIS AND HAEMOSTASIS, 2004, 91 (06) : 1123 - 1128
  • [4] Allelic and functional variability of cytochrome P4502C9
    Bhasker, CR
    Miners, JO
    Coulter, S
    Birkett, DJ
    PHARMACOGENETICS, 1997, 7 (01): : 51 - 58
  • [5] Clinical consequences of cytochrome P4502C9 polymorphisms
    Kirchheiner, J
    Brockmöller, J
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (01) : 1 - 16
  • [6] Inhibitory effect of 5-fluorouracil on cytochrome P4502C9 activity in cancer patients
    Gunes, A
    Coskun, U
    Boruban, C
    Gunel, N
    Babaoglu, MO
    Sencan, O
    Bozkurt, A
    Rane, A
    Hassan, M
    Zengil, H
    Yasar, U
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2006, 98 (02) : 197 - 200
  • [7] Cytochrome P4502C9 activity in end-stage renal disease
    Dreisbach, AW
    Japa, S
    Gebrekal, AB
    Mowry, SE
    Lertora, JJL
    Kamath, BL
    Rettie, AE
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (05) : 475 - 477
  • [8] Tamoxifen inhibits cytochrome P4502C9 activity in breast cancer patients
    Boruban, M. C.
    Yasar, U.
    Babaoglu, M. O.
    Sencan, O.
    Bozkurt, A.
    JOURNAL OF CHEMOTHERAPY, 2006, 18 (04) : 421 - 424
  • [9] The risk of myocardial infarction in patients with reduced activity of cytochrome P4502C9
    Visser, Loes E.
    van Schaik, Ron H. N.
    Danser, Alexander H. Jan
    Hofman, Albert
    Witteman, Jacqueline C. M.
    van Duijn, Cornelia M.
    Uitterlinden, Andre G.
    Pols, Huibert A. P.
    Stricker, Bruno H. Ch.
    PHARMACOGENETICS AND GENOMICS, 2007, 17 (07): : 473 - 479
  • [10] Lornoxicam pharmacokinetics in relation to cytochrome P4502C9 genotype
    Zhang, YF
    Zhong, DF
    Si, DY
    Guo, YJ
    Chen, XY
    Zhou, H
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 59 (01) : 14 - 17